Mo Z S, Xie D Y, Lin B L, Dou X G, Wan M B, Jiang J J, Zhao Y R, Tang H, Zhuang H, Gao Z L
Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang 110000, China.
Zhonghua Gan Zang Bing Za Zhi. 2024 May 20;32(5):411-417. doi: 10.3760/cma.j.cn501113-20240325-00156.
Clinical cure (herein referred to as functional cure) is currently recognized as the ideal therapeutic goal by the guidelines for the prevention and treatment of chronic hepatitis B (CHB) at home and abroad. China has achieved significant results in research and exploration based on pegylated interferon alpha therapeutic strategies to promote the effectiveness of CHB clinical cure rates in clinical practice. The summary and optimization of clinical cure strategies in different clinical type classifications, as well as the exploration of clinical cure continuity and long-term outcomes, are of great significance for solving the current bottleneck problem and our future efforts in the developmental directions of clinical cure in CHB populations.
临床治愈（以下简称功能性治愈）目前被国内外慢性乙型肝炎（CHB）防治指南公认为理想的治疗目标。我国基于聚乙二醇化干扰素α治疗策略开展研究探索，在提高CHB临床治愈率方面取得了显著成效。对不同临床类型分类的临床治愈策略进行总结和优化，以及对临床治愈的持续性和长期结局进行探索，对于解决当前的瓶颈问题以及我国未来在CHB人群临床治愈发展方向上的努力具有重要意义。
